脂筏相关蛋白flotillin 2在髓系白血病进展中的差异性作用
该研究利用小鼠移植模型,探讨脂筏相关蛋白FLOT2在白血病起始细胞(LIC)中对BCR-ABL1+慢性髓系白血病(CML)和MLL-AF9驱动的急性髓系白血病(AML)疾病进程的影响。结果显示,FLOT2缺失仅改变CML病程而不影响AML;FLOT2缺失的BCR-ABL1+ LIC出现细胞骨架、细胞极性和归巢能力缺陷,并涉及CD44-CDC42轴。
要点
- FLOT2缺失改变BCR-ABL1+ CML病程,但不影响MLL-AF9+ AML病程。
- FLOT2为CML和AML的LIC表达CD44所必需。
- 仅FLOT2缺失的BCR-ABL1+细胞出现细胞骨架、极性和归巢缺陷。
核心结论
- 数据提示FLOT2-CD44-CDC42轴差异性调控CML与AML进展,FLOT2缺失损害CML发展。
研究设计与样本
- 研究采用小鼠移植模型,比较FLOT2缺失对BCR-ABL1+ CML和MLL-AF9驱动AML的LIC及疾病进程的影响。
主要发现
- FLOT2缺失改变BCR-ABL1+ CML病程,但不改变MLL-AF9驱动的AML病程。
- FLOT2为CML-LIC和AML-LIC表达CD44所必需。
- 仅FLOT2缺失的BCR-ABL1+细胞较MLL-AF9+细胞出现细胞骨架、细胞极性缺陷及LIC归巢能力受损。
- 在CD44下游,野生型与FLOT2缺失的人CML和AML细胞间观察到不依赖BCR-ABL1激酶的CDC42表达、定位和活性差异。
- ML141抑制CDC42损害CML LIC归巢,进而影响CML进展。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lipid raft-associated proteins play a vital role in membrane-mediated processes. The lipid microdomain-associated protein flotillin 2 (FLOT2), which has a scaffolding function, is involved in polarization, as well as in actin cytoskeletal organization of primitive and mature hematopoietic cells and has been associated with different malignancies. However, its involvement in myeloid leukemias is not well studied. Using murine transplantation models, we show here that the absence of FLOT2 from leukemia-initiating cells (LICs) altered the disease course of BCR-ABL1+ chronic myeloid leukemia (CML), but not of MLL-AF9-driven acute myeloid leukemia (AML). While FLOT2 was required for expression of the adhesion molecule CD44 on both CML- and AML-LIC, a defect in the cytoskeleton, cell polarity, and impaired homing ability of LIC was only observed in FLOT2-deficient BCR-ABL1+ compared with MLL-AF9+ cells. Downstream of CD44, BCR-ABL1 kinase-independent discrepancies were observed regarding expression, localization, and activity of cell division control protein 42 homolog (CDC42) between wild-type (WT) and FLOT2-deficient human CML and AML cells. Inhibition of CDC42 by ML141 impaired the homing of CML LIC and, thereby, CML progression. This suggested that alteration of both CD44 and CDC42 may be causative of impaired CML progression in the absence of FLOT2. In summary, our data suggest a FLOT2-CD44-CDC42 axis, which differentially regulates CML vs AML progression, with deficiency of FLOT2 impairing the development of CML.
引用
- Kumar R, Pereira RS, Niemann J, et al. The differential role of the lipid raft-associated protein flotillin 2 for progression of myeloid leukemia. Blood Adv. 2022. PMID: 35298613. doi:10.1182/bloodadvances.2021005992
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。